



^c GEROM Groupe Etudes Remodelage Osseux et bioMatériaux – LHEA, IRIS-IBS Institut de Biologie en Santé, CHU d'Angers, 49933 Angers Cedex, France

Recently, another mechanism has been highlighted in inducing a favorable local microenvironment for tumor growth: membrane-derived vesicles (MPs) shed from different cell types (Peinado et al., 2011). MPs are membrane-derived vesicles (diameter $\leq 1 \mu\text{m}$) that are released during cell activation or apoptosis. On their surface, MPs bear antigens characteristic of the cell of origin, and carry other membrane and cytoplasmic constituents. MPs are present in blood from healthy and non-healthy individuals leading to the hypothesis that they may play physiological and/or pathophysiological roles. Previous studies have revealed various roles of MPs in cancer. It has been recently shown that MPs can induce in vitro neo-angiogenesis which might contribute to the generation of a vascular network in malignant disease associated with tumor growth (Soleti et al., 2009). In addition, MPs released from tumor cells have a pro-angiogenic activity (Kim et al., 2002). Other membrane compounds linked to MPs, such as urokinase, can increase the invasive capacity of prostate cancer cells (Angelucci et al., 2000). MPs are able to carry intercellular signals allowing the tumor survival and progression. Considering that enhanced levels of circulating MPs have been detected in patients with different types of cancers, one can advanced the hypothesis that MPs might play an important role in the tumor development (Martinez and Andriantsitohaina, 2011; Mostefai et al., 2008; Tual-Chalot et al., 2011).

Because of the various cell types involved in MM and the strong interaction of the bone and medullar microenvironment, we hypothesized an implication of MPs in the development of MM. In the present study, quantification and characterization of both circulating-MPs and BM-derived MPs were investigated in the 5THL murine model of MM.

2. Materials and methods

2.1. Mice

C57BL/KaLwRij female mice (6–8-week-old) were used for the study (Harlan, Gannat, France). They were acclimated for 1 week to the local vivarium conditions (24 °C and 12 h/12 h light/dark cycle) where they were given standard laboratory food (UAR, Villemoisson sur Orge, France) and water ad libitum. The Animal Care and Use committee at the University of Angers approved all procedures.

2.2. Culture cell line

We have used the 5THL cell line as previously characterized (Libouban et al., 2004). Briefly, the 5THL cell line is an aggressive subline of 5T2MM cell line originating from elderly C57BL/KaLwRij mice that spontaneously developed MM (Croese et al., 1987). 5THL cells can be propagated into young syngeneic mice by intravenous transfer of the diseased BM. Progression of the disease in seven recipient mice was assessed by measuring the serum M-protein (IgG2ak) level using agar electrophoresis (Hydragel Protein, SEBIA, Issy les Moulineaux, France). Around 6 week post-injection of 5THL, mice had a detectable serum M-protein and were euthanized after 10–12 weeks by cervical dislocation. Femurs and tibias were dissected, cleaned of surrounding tissues and BM was flushed in Dulbecco's modified essential medium (DMEM.mod, GIBCO, Life Technologies, France) supplemented with penicillin–streptomycin, amphotericin–fungizone and pyruvate. BM cells were washed once in DMEM.mod. Mononuclear cells were isolated by a Lympholyte-M centrifugation gradient (Cedarlane, Hornby, Ontario, Canada) at $1250 \times g$ for 20 min. Mononuclear cells were then washed twice in DMEM.mod and counted.

2.3. Experimental design

Forty-four mice (6–8 weeks old) were injected with 1.5×10^6 5THL cells in the tail vein and 14 non-injected mice were used as control (CTL). The injected mice were divided in 2 groups according to the time of sacrifice. At 6 weeks, corresponding to the early stage of MM development, 14 mice were bled before being sacrificed by cervical dislocation. These mice constituted the early stage MM group (EMM) and were used to quantify and characterize the phenotype of circulating MPs. At the end stage of the disease (10–12 weeks), when osteolysis can be evidenced on X-ray images, the remaining 30 mice were bled before being sacrificed by cervical dislocation. These mice constituted the late stage MM group (LMM) and were used to quantify and characterize the phenotype of circulating MPs (see below). Twenty-two mice from the LMM group were also used to isolate MPs from the BM of femurs and tibias. The 14 non-injected mice (16–18-week-old) were bled as previously described to quantify and phenotype circulating MPs. Eight of the 14 mice were also used to isolate MPs from BM.

Two additional mice injected with 5THL cells were sacrificed at the end stage of the disease and were used for transmission electron microscopy (TEM) observations and immunohistochemistry of BM-derived MPs and MM cells.

2.4. Circulating MP isolation and characterization

C57BL/KaLwRij mice at 6 weeks or at 10–12 weeks were anesthetized using Isoflurane (Baxter, Maurepas, France) before sacrifice, and $\sim 800 \mu\text{l}$ of blood were collected by aspiration from the left ventricle. Blood was placed in citrated tubes and centrifuged at $1900 \times g$ for 3 min for separation of platelet-rich plasma from whole blood. Then, platelet-rich plasma was centrifuged at $5000 \times g$ for 4 min to obtain platelet-free plasma (PFP). Sixty microliters of PFP were frozen and stored at -80°C until subsequent use. In order to pellet MPs for in vitro studies, circulating MPs were concentrated from PFP by three series of centrifugations at $21,000 \times g$ for 45 min and re-suspended in saline and stored at 4°C until subsequent use.

Membrane MP subpopulations were discriminated in PFP according the expression of membrane-specific antigens. Phenotype of endothelial MPs was performed using anti-CD54 labeling; characterization of platelet, leukocyte and erythrocyte MPs was performed using respectively anti-CD61, anti-CD45 and Ter-119/erythroid cell labeling. Irrelevant mouse IgG was used as an isotype-matched negative control for each sample.

For numeration studies, $8 \mu\text{l}$ of PFP were incubated with either $1 \mu\text{l}$ of specific antibody (BioLegend, San Diego, CA). After 45 min of incubation at room temperature, samples were diluted in $300 \mu\text{l}$ of saline. Annexin V (BioVision, Inc., Mountain View, CA) binding was used to numerate circulating phosphatidylserine-expressing MPs ($2 \mu\text{l}$ of annexin V/ $5 \mu\text{l}$ PFP). Then, in order to enumerate MPs, an equal volume of sample and Flowcount beads were added and samples were analyzed in a flow cytometer 500 MPL system (Beckman Coulter, Roissy, France) as previously described (Agouni et al., 2008; Mostefai et al., 2008). Flow-count fluorospheres consist of $10 \mu\text{m}$ polystyrene fluorospheres in an aqueous suspension medium. Each fluorosphere contains a dye that has a fluorescence emission range of 525–700 nm when excited at 488 nm. The concentration of each lot of Flow-count fluorospheres is derived from multiple replicate analyses on a COULTER particle size analyzer performed by the manufacturer. Each lot of Flow-count fluorospheres has a specific concentration of fluorospheres. When identical volumes of a sample and Flow-count fluorospheres are used, a ratio of MPs in the sample to fluorospheres is established. Since the concentration of fluorospheres is known, the absolute count of the MPs can be automatically determined by the MXP software.

Download English Version:

<https://daneshyari.com/en/article/1589070>

Download Persian Version:

<https://daneshyari.com/article/1589070>

[Daneshyari.com](https://daneshyari.com)